Early intervention and the treatment of prodrome in schizophrenia: A review of recent developments

Journal of Psychiatric Practice

Volumn 19, Issue 5, 2013, Pages 375-385

  Mokhtari, Mohammadreza ^a   Rajarethinam, Rajaprabhakaran ^b,c  

^a HARTFORD HOSPITAL   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c ST MARY MERCY HOSPITAL   (United States)

Author keywords

Early intervention; Prevention; Prodrome; Psychosis; Schizophrenia

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID; RISPERIDONE;

CLINICAL FEATURE; COGNITIVE THERAPY; EARLY INTERVENTION; FOLLOW UP; HIGH RISK POPULATION; HUMAN; OUTCOME ASSESSMENT; POSITIVE SYNDROME; PREDICTIVE VALUE; PSYCHOPHARMACOTHERAPY; REVIEW; RISK ASSESSMENT; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; EARLY DIAGNOSIS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PRODROMAL SYMPTOMS; RISK FACTORS; SCHIZOPHRENIA;

EID: 84884999589     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pra.0000435036.83426.94     Document Type: Review

References (103)

1. Editorial. Where next with psychiatric illness? Nature 1988;336:95-6.
2. World Health Organization Mental Health Report 2001. Mental health: New understanding, new hope. Geneva: World Health Organization, 2001
3. Van Os J, Kapur S. Schizophrenia. Lancet 2009;374: 635-45.
4. Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, just the facts 4. Clinical features and conceptualization. Schizophr Res 2009;110:1-23.
5. Rssler W, Salize HJ, van Os J, et al. Size of burden of schizophrenia and psychotic disorders. Eur Neuropsycho - pharmacol 2005;15:399-409.
6. Caplan G. Principles of preventive psychiatry. New York: Basic Books, 1964 as cited in
7. Lee C, McGlashan TH, Woods SW. Prevention of schizophrenia, can it be achieved? CNS Drugs 2005;19:193-206.
8. Challenges in preventing schizophrenia; A major hurdle is identifying those at risk for developing psychosis in the future. Harv Ment Health Lett 2009;26:4-5.
9. McGorry PD, Nelson B, Amminger GP, et al. Intervention in individuals at ultra-high risk for psychosis: A review and future directions. J Clin Psychiatry 2009;70:1206-12.
10. Marshall M, Lewis S, Lockwood A, et al. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: A systematic review. Arch Gen Psychiatry 2005;62:975-83.
11. Keshavan MS, Amirsadri A. Early intervention in schizophrenia: Current and future perspectives. Curr Psychiatry Rep 2007;9:325-8.
12. Yung AR, Killackey E, Hetrick SE, et al. The prevention of schizophrenia. Int Rev Psychiatr 2007;19:633-46.
13. Woods SW, McGlashan TH. Schizophrenia and other psychotic disorders: Special issues in early detection and intervention. In: Sadock BJ, Sadock VA, eds. Kaplan &Sadocks comprehensive textbook of psychiatry, 8th edition. Philadelphia: Lippincott Williams &Wilkins; 2005: 1551-9.
14. Schenkel LS, Silverstein SM. Dimensions of premorbid functioning in schizophrenia: A review of neuromotor, cognitive, social, and behavioral domains. Genet Soc Gen Psychol Monogr 2004;130:241-70.
15. Yung AR, Phillips LJ, Yuen HP, et al. Psychosis prediction: 12-month follow up of a high-risk (prodromal) group. Schizophr Res 2003;60:21-32.
16. Sullivan HS. The onset of schizophrenia. 1927. Am J Psychiatry 1994;151:134-9.
17. Cameron DE. Early schizophrenia. Am J Psychiatry 1938; 95:567-78.
18. Compton MT. Considering schizophrenia from a prevention perspective. Am J Prev Med 2004;26:178-85.
19. McGorry PD, Killackey E, Yung AR. Early intervention in psychotic disorders: Detection and treatment of the first episode and the critical early stages. Med J Aust 2007;187: S8-10.
20. Mrazek PJ, Haggerty RJ, eds. Reducing risks for mental disorders: Frontiers for preventive intervention research. Washington, DC: National Academy of Sciences, 1994 (available at http://books.nap.edu/catalog/2139.html, acessed October 28,2012).
21. Faraone SV, Brown CH, Glatt SJ, et al. Preventing schizophrenia and psychotic behaviour: Definitions and methodological issues. Can J Psychiatry 2002;47:527-37.
22. Byrne M, Agerbo E, Bennedsen B, et al. Obstetric conditions and risk of first admission with schizophrenia: A Danish national register based study. Schizophr Res 2007;97:51-9.
23. Van Os J, Delespaul P. Toward a world consensus on prevention of schizophrenia. Dialogues Clin Neurosci 2005;7: 53-67.
24. Joa I, Johannessen JO, Auestad B, et al. The key to reducing duration of untreated first psychosis: Information campaigns. Schizophr Bull 2008;34:466-72.
25. Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: A systematic review. Lancet 2007;370:319-28.
26. Hedelin M, Lof M, Olsson M, et al. Dietary intake of fish, omega-3, omega-6 polyunsaturated fatty acids and vitamin D and the prevalence of psychotic-like symptoms in a cohort of 33,000 women from the general population. BMC Psychiatry 2010;10:38.
27. Peet M, Stokes C. Omega-3 fatty acids in the treatment of psychiatric disorders. Drugs 2005;65:1051-9.
28. Editorial. Is it time to trial vitamin D supplements for the prevention of schizophrenia? Acta Psychiatr Scand 2010; 121:321-4.
29. Warner R. The prevention of schizophrenia: What interventions are safe and effective? Schizophr Bull 2001;27: 551-62.
30. Beauchaine TP, Neuhaus E, Brenner SL, et al. Ten good reasons to consider biological processes in prevention and intervention research. Dev Psychopathol 2008;20:745-74.
31. Tienari P, Wynne LC, Sorri A, et al. Genotype-environment interaction in schizophrenia spectrum disorder: Long-term follow-up study of Finnish adoptees. Br J Psychiatry 2004; 184:216-22.
32. Tandon R, Keshavan MS, Nasrallah HA. Schizophrenia, just the facts what we know in 2008. 2. Epidemiology and etiology. Schizophr Res 2008;102:1-18.
33. Mki P, Veijola J, Jones PB, et al. Predictors of schizophrenia- A review. Br Med Bull 2005;73/74:1-15.
34. Read J, van Os J, Morrison AP, et al. Childhood trauma, psychosis and schizophrenia: A literature review with theoretical and clinical implications. Acta Psychiatr Scand 2005; 112:330-50.
35. Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait: Evidence from a meta-analysis of twin studies. Arch Gen Psychiatry 2003;60:1187-92.
36. Allen NC, Bagade S, McQueen MB, et al. Systematic metaanalyses and field synopsis of genetic association studies in schizophrenia: The SzGene database. Nat Genet 2008; 40:827-34.
37. Wray NR, Visscher PM. Narrowing the boundaries of the genetic architecture of schizophrenia. Schizophr Bull 2010;36:14-23.
38. Hans SL, Auerbach JG, Auerbach AG, et al. Development from birth to adolescence of children at-risk for schizophre- nia. J Child Adolesc Psychopharmacol 2005;15: 384-94.
39. Fish B. Neurobiologic antecedents of schizophrenia in children: Evidence for an inherited, congenital, neurointegrative defect. Arch Gen Psychiatry 1977;34:1297-313.
40. Fish B, Kendler KS. Abnormal infant neurodevelopment predicts schizophrenia spectrum disorders. J Child Adolesc Psychopharmacol 2005;15:348-36.
41. Keshavan M, Montrose DM, Rajarethinam R, et al. Psychopathology among offspring of parents with schizophrenia: Relationship to premorbid impairments. Schizophr Res 2008;103:114-20.
42. Ross RG, Compagnon N. Diagnosis and treatment of psychiatric disorders in children with a schizophrenic parent. Schizophr Res 2001;50:121-9.
43. Donatelli JA, Seidman LJ, Goldstein JM, et al. Children of parents with affective and nonaffective psychoses: A longitudinal study of behavior problems. Am J Psychiatry 2010; 167:1331-8.
44. Carlson GA, Fish B. Longitudinal course of schizophrenia spectrum symptoms in offspring of psychiatrically hospitalized mothers. J Child Adolesc Psychopharmacol 2005;15: 362-83.
45. Boos HB, Aleman A, Cahn W, et al. Brain volumes in relatives of patients with schizophrenia: A meta-analysis. Arch Gen Psychiatry 2007;64:297-304.
46. Keshavan MS, Diwadkar VA, Spencer SM, et al. A preliminary functional magnetic resonance imaging study in offspring of schizophrenic parents. Prog Neuro psychopharmacol Biol Psychiatry 2002;26:1143-9.
47. Prasad KM, Goradia D, Eack S, et al. Cortical surface characteristics among offspring of schizophrenia subjects. Schizophr Res 2010;116:143-51.
48. McDonald C, Grech A, Toulopoulou T, et al. Brain volumes in familial and non-familial schizophrenic probands and their unaffected relatives. Am J Med Genet 2002;114: 616-25.
49. Ho BC. MRI brain volume abnormalities in young, nonpsychotic relatives of schizophrenia probands are associated with subsequent prodromal symptoms. Schizophr Res 2007;96:1-13.
50. Karch S, Leicht G, Giegling I, et al. Inefficient neural activity in patients with schizophrenia and nonpsychotic relatives of schizophrenic patients: Evidence from a working memory task. J Psychiatr Res 2009;43:1185-94.
51. Bhojraj TS, Diwadkar VA, Sweeney JA, et al. Longitudinal alterations of executive function in non-psychotic adolescents at familial risk for schizophrenia. Prog Neuro - psychopharmacol Biol Psychiatry 2010;34:469-74.
52. Venables NC, Bernat EM, Sponheim SR. Genetic and disorder- specific aspects of resting state EEG abnormalities in schizophrenia. Schizophr Bull 2009;35:826-39.
53. Thaker GK. Neurophysiological endophenotypes across bipolar and schizophrenia psychosis. Schizophr Bull 2008; 34:760-73.
54. Ziermans TB, Schothorst PF, Sprong M, et al. Reduced prepulse inhibition as an early vulnerability marker of the psychosis prodrome in adolescence. Schizophr Res 2012; 134:10-5.
55. Schenkel LS, Silverstein SM. Dimensions of premorbid functioning in schizophrenia: A review of neuromotor, cognitive, social, and behavioral domains. Genet Soc Gen Psychol Monogr 2004;130:241-70.
56. Isohanni M, Isohanni I, Koponen H, et al. Developmental precursors of psychosis. Curr Psychiatry Rep 2004;6: 168-75.
57. Woods SW, Addington J, Cadenhead KS, et al. Validity of the prodromal risk syndrome for first psychosis: Findings from the North American prodrome longitudinal study. Schizophr Bull 2009;35:894-908.
58. Corcoran CM, First MB, Cornblatt B. The psychosis risk syndrome and its proposed inclusion in the DSM-V: A riskbenefit analysis. Schizophr Res 2010;120:16-22.
59. Woods SW, Walsh BC, Saksa JR, et al. The case for including attenuated psychotic symptoms syndrome in DSM-5 as a psychosis risk syndrome. Schizophr Res 2010;123: 199-207.
60. American Psychiatric Association. DSM-5 development (available at www.dsm5.org/Pages/RecentUpdates.aspx, accessed July 31, 2013).
61. Moller P, Husby R. The initial prodrome in schizophrenia: Searching for naturalistic core dimensions of experience and behavior. Schizophr Bull 2000;26:217-32.
62. Olsen KA, Rosenbaum B. Prospective investigations of the prodromal state of schizophrenia: Review of studies. Acta Psychiatr Scand 2006;113:247-72.
63. Cannon TD, Cadenhead K, Cornblatt B, et al. Prediction of psychosis in youth at high clinical risk: A multisite longitudinal study in North America. Arch Gen Psychiatry 2008;65:28-37.
64. Ruhrmann S, Schultze-Lutter F, Klosterkotter J. Early detection and intervention in the initial prodromal phase of schizophrenia. Pharmacopsychiatry 2003;36:S162-7.
65. Tandon N, Shah J, Keshavan M, et al. Attenuated psychosis and the schizophrenia prodrome: Current status of risk identification and psychosis prevention. Neuropsy chiatry 2012;2:345-53.
66. Gee DG, Cannon TD. Prediction of conversion to psychosis: Review and future directions. Rev Bras Psiquiatr 2011;33: s129-42.
67. Fusar-Poli P, Deste G, Smieskova R, et al. Cognitive functioning in prodromal psychosis: A meta-analysis. Arch Gen Psychiatry 2012;69:562-71.
68. Schlosser DA, Jacobson S, Chen Q. Recovery from an at-risk state: Clinical and functional outcomes of putatively prodromal youth who do not develop psychosis. Schizophr Bull 2012;38:1225-33.
69. Lin A, Wood SJ, Nelson B, et al. Neurocognitive predictors of functional outcome two to 13 years after identification as ultra-high risk for psychosis. Schizophr Res 2011;132: 1-7.
70. de Koning MB, Bloemen ON, van Amelsvoort TM, et al. Early intervention in patients at ultra high risk of psychosis: Benefits and risks. Acta Psychiatr Scand 2009:119: 426-42.
71. Yung AR, McGorry PD, Francey SM, et al. PACE: A specialised service for young people at risk of psychotic disorders. Med J Aust 2007;187:S43-6.
72. Singh SP. Early intervention in psychosis. Br J Psychiatry 2010;196:343-5.
73. McGorry PD, Yung AR, Phillips LJ, et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 2002; 59:921-8.
74. Phillips LJ, McGorry PD, Yuen HP, et al. Medium term follow- up of a randomized controlled trial of interventions for young people at ultra high risk of psychosis. Schizophr Res 2007;96:25-33.
75. McGlashan TH, Zipursky RB, Perkins D, et al. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. Schizophr Res 2003;61:7-18.
76. Miller TJ, Zipursky RB, Perkins D, et al. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the prodromal sample. Schizophr Res 2003; 61:19-30.
77. McGlashan TH, Zipursky RB, Perkins D, et al. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006;163:790-9.
78. Miller TJ, McGlashan TH, Woods SW, et al. Symptom assessment in schizophrenic prodromal states. Psychiatric Quarterly 1999;70:273-87.
79. Miller TJ, McGlashan TH, Rosen JL, et al. Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: Preliminary evidence of interrater reliability and predictive validity. Am J Psychiatry 2002;159:863-5.
80. Miller TJ, McGlashan TH, Rosen JL, et al. Prodromal assess ment with the structured interview for prodromal syndromes and the Scale of Prodromal Symptoms: Predictive validity, interrater reliability, and training to reliability. Schizophr Bull 2003;29:703-15.
81. Ruhrmann S, Bechdolf A, Khn KU, et al. Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. Br J Psychiatry Suppl 2007;51:S88-95.
82. Hafner H, Riecher-Rossler A, Hambrecht M, et al. IRAOS: An instrument for the assessment of onset and early course of schizophrenia. Schizophr Res 1992;6:209-23.
83. Cornblatt BA, Lencz T, Smith CW, et al. Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. J Clin Psychiatry 2007;68:546-57.
84. Amminger GP, Schfer MR, Papageorgiou K, et al. Longchain omega-3 fatty acids for indicated prevention of psychotic disorders: A randomized, placebo-controlled trial. Arch Gen Psychiatry 2010;67:146-54.
85. Potvin S, Stip E, Sepehry AA, et al. Inflammatory cytokine alterations in schizophrenia: A systematic quantitative review. Biol Psychiatry 2008;63:801-8.
86. Morrison AP, French P, Walford L, et al. Cognitive therapy for the prevention of psychosis in people at ultra-high risk: Randomised controlled trial. Br J Psychiatry 2004;185: 291-7.
87. Morrison AP, French P, Parker S, et al. Three-year follow-up of a randomized controlled trial of cognitive therapy for the prevention of psychosis in people at ultrahigh risk. Schizophr Bull 2007;33:682-7.
88. Nordentoft M, Thorup A, Petersen L, et al. Transition rates from schizotypal disorder to psychotic disorder for first-contact patients included in the OPUS trial: A randomized clinical trial of integrated treatment and standard treatment. Schizophr Res 2006;83:29-40.
89. Morrison AP, Bentall RP, French P, et al. Randomised controlled trial of early detection and cognitive therapy for preventing transition to psychosis in high-risk individuals: Study design and interim analysis of transition rate and psychological risk factors. Br J Psychiatry Suppl 2002;43:S78-84.
90. Miller TJ, McGlashan TH, Rosen JL, et al. Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: Preliminary evidence of interrater reliability and predictive validity. Am J Psychiatry 2002;159:863-5.
91. Addington J, Cornblatt BA, Cadenhead KS, et al. At clinical high risk for psychosis: Outcome for nonconverters. Am J Psychiatry 2011;168:800-5.
92. Warner R. Problems with early and very early intervention in psychosis. Br J Psychiatry 2005;187:S104-7.
93. Raven M, Stuart GW, Jureidini J. Prodromal diagnosis of psychosis: Ethical problems in research and clinical practice. Aust N Z J Psychiatry 2012;46:64-5.
94. Marshall M, Rathbone J. Early intervention for psychosis. Cochrane Database Syst Rev 2006;Oct 18;(4)CD004718.
95. McGlashan TH, Addington J, Cannon T, et al. Recruitment and treatment practices for help-seeking prodromal patients. Schizophr Bull 2007;33:715-26.
96. Ruhrmann S, Schultze-Lutter F, Klosterktter J. Probably at-risk, but certainly ill. Advocating the introduction of a psychosis spectrum disorder in DSM-V. Schizophr Res 2010;120:23-37.
97. Yung AR, Nelson B, Baker K, et al. Psychotic-like experiences in a community sample of adolescents: Implications for the continuum model of psychosis and prediction of schizophrenia. Aust NZ J Psychiatry 2009;43:118-28.
98. Svirskis T, Korkeila J, Heinimaa M, et al. Axis-I disorders and vulnerability to psychosis. Schizophr Res 2005;75: 439-46.
99. Fusar-Poli P, Byrne M, Valmaggia L, et al. Social dysfunction predicts two years clinical outcome in people at ultra high risk for psychosis. J Psychiatr Res 2010;44:294-301.
100. Yung AR. Antipsychotic treatment of UHR prodromal individuals. Early Interv Psychiatry 2010;4:197-9.
101. Nelson B, Yung AR. Can clinicians predict psychosis in an ultra high risk group? Aust NZ J Psychiatry 2010;44: 625-30.
102. International Early Psychosis Association, Addington J, Amminger GP, et al. International clinical practice guidelines for early psychosis. Br J Psychiatry 2005;187:120-4.
103. McCrone P, Craig TK, Power P, et al. Cost-effectiveness of an early intervention service for people with psychosis. Br J Psychiatry 2010;196:377-82.